Windael Simon, Vervaeke Stijn, De Buyser Stefanie, De Bruyn Hugo, Collaert Bruno
School of Dental Medicine, Department of Periodontology and Oral Implantology, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.
Private Practice Periodontology and Oral Implantology, 8940 Geluwe, Belgium.
J Clin Med. 2020 Apr 8;9(4):1056. doi: 10.3390/jcm9041056.
The purpose of this study was to compare the survival and peri-implant bone loss of implants with a fluoride-modified surface in smokers and non-smokers.
All patients referred for implant treatment between November 2004 and 2007 were scrutinized. All implants were placed by the same surgeon (B.C.). The single inclusion criterion was a follow-up time of at least 10 years. Implant survival, health, and bone loss were evaluated by an external calibrated examiner (S.W.) during recall visits. Radiographs taken at recall visits were compared with the post-surgical ones. Implant success was based on two arbitrarily chosen success criteria for bone loss (≤1 mm and ≤2 mm bone loss after 10 years). Implant survival in smokers and non-smokers was compared using the log-rank test. Both non-parametric tests and fixed model analysis were used to assess bone loss in both groups.
A total of 453 implants in 121 patients were included for survival analysis, and 397 implants in 121 patients were included for peri-implant bone-loss analysis. After a mean follow-up time of 11.38 years (SD 0.78; range 10.00-13.65), 33 implants out of 453 initially placed had failed in 21 patients, giving an overall survival rate of 92.7% and 82.6% on the implant and patient level, respectively. Cumulative 10 years' survival rate was 81% on the patient level and 91% on the implant level. The hazard of implant loss in the maxilla was 5.64 times higher in smokers compared to non-smokers ( = 0.003). The hazard of implant loss for implants of non-smokers was 2.92 times higher in the mandible compared to the maxilla ( = 0.01). The overall mean bone loss was 0.97 mm (SD 1.79, range 0-17) at the implant level and 0.90 mm (SD 1.39, range 0-7.85) at the patient level. Smokers lost significantly more bone compared to non-smokers in the maxilla ( = 0.024) but not in the mandible. Only the maxilla showed a significant difference in the probability of implant success between smokers and non-smokers (≤1 mm criterion = 0.003, ≤2 mm criterion = 0.007). Taking jaw into account, implants in smokers experienced a 2.6 higher risk of developing peri-implantitis compared to non-smokers ( = 0.053).
Dental implants with a fluoride-modified surface provided a high 10 years' survival with limited bone loss. Smokers were, however, more prone to peri-implant bone loss and experienced a higher rate of implant failure, especially in the upper jaw. The overall bone loss over time was significantly higher in smoking patients, which might be suggestive for a higher peri-implantitis risk. Hence, smoking cessation should be advised and maintained after implant placement from the perspective of peri-implant disease prevention.
本研究的目的是比较吸烟者和非吸烟者中具有氟改性表面的种植体的存活率和种植体周围骨丢失情况。
对2004年11月至2007年期间所有接受种植治疗的患者进行了仔细审查。所有种植体均由同一位外科医生(B.C.)植入。唯一的纳入标准是随访时间至少为10年。在复诊时,由一名外部校准检查人员(S.W.)评估种植体的存活率、健康状况和骨丢失情况。将复诊时拍摄的X线片与术后的X线片进行比较。种植成功基于两个任意选定的骨丢失成功标准(10年后骨丢失≤1mm和≤2mm)。使用对数秩检验比较吸烟者和非吸烟者中种植体的存活率。采用非参数检验和固定模型分析来评估两组中的骨丢失情况。
共有121例患者的453枚种植体纳入存活率分析,121例患者的397枚种植体纳入种植体周围骨丢失分析。平均随访11.38年(标准差0.78;范围10.00 - 13.65)后,最初植入的453枚种植体中有33枚在21例患者中失败,种植体水平和患者水平的总体存活率分别为92.7%和82.6%。患者水平的10年累积存活率为81%,种植体水平为91%。吸烟者上颌种植体丢失的风险是非吸烟者的5.64倍(P = 0.003)。非吸烟者下颌种植体丢失的风险是上颌的2.92倍(P = 0.01)。种植体水平的总体平均骨丢失为0.97mm(标准差1.79,范围0 - 17),患者水平为0.90mm(标准差1.39,范围0 - 7.85)。吸烟者在上颌的骨丢失明显多于非吸烟者(P = 0.024),但在下颌并非如此。仅上颌在吸烟者和非吸烟者的种植成功概率上存在显著差异(≤1mm标准P = 0.003,≤2mm标准P = 0.007)。考虑到颌骨,吸烟者的种植体发生种植体周围炎的风险比非吸烟者高2.6倍(P = 0.053)。
具有氟改性表面的牙种植体在10年时具有较高的存活率且骨丢失有限。然而,吸烟者更容易发生种植体周围骨丢失,且种植失败率更高,尤其是在上颌。随着时间推移,吸烟患者的总体骨丢失明显更高,这可能提示种植体周围炎风险更高。因此,从预防种植体周围疾病的角度出发,建议在种植体植入后戒烟并保持戒烟状态。